PRAMEF2

Across TCGA pan-cancer cohorts, PRAMEF2 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of PRAMEF2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where PRAMEF2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRAMEF2 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

LUAD and THCA are the cancer types where PRAMEF2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRAMEF2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	All	+0.020	.011	2	view →
THCA	All	All	−0.017	.008	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

PRAMEF2–LUAD

Open the LUAD breakdown →